PALLESCHI, MICHELA
 Distribuzione geografica
Continente #
AS - Asia 2.087
NA - Nord America 651
EU - Europa 549
SA - Sud America 104
AF - Africa 45
OC - Oceania 1
Totale 3.437
Nazione #
VN - Vietnam 675
US - Stati Uniti d'America 626
SG - Singapore 571
CN - Cina 498
IT - Italia 154
HK - Hong Kong 153
NL - Olanda 135
KR - Corea 102
BR - Brasile 84
DE - Germania 69
FI - Finlandia 45
IN - India 33
SE - Svezia 29
CI - Costa d'Avorio 28
FR - Francia 24
JP - Giappone 21
ID - Indonesia 17
IE - Irlanda 17
GB - Regno Unito 16
RU - Federazione Russa 15
AT - Austria 12
MX - Messico 12
SC - Seychelles 10
CA - Canada 8
AR - Argentina 7
CH - Svizzera 7
PL - Polonia 7
BD - Bangladesh 6
BG - Bulgaria 6
JO - Giordania 6
BE - Belgio 4
EC - Ecuador 4
CO - Colombia 3
CZ - Repubblica Ceca 3
BO - Bolivia 2
CR - Costa Rica 2
EG - Egitto 2
ES - Italia 2
LT - Lituania 2
MA - Marocco 2
TG - Togo 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
DO - Repubblica Dominicana 1
GH - Ghana 1
LV - Lettonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PK - Pakistan 1
PY - Paraguay 1
UY - Uruguay 1
UZ - Uzbekistan 1
VC - Saint Vincent e Grenadine 1
Totale 3.437
Città #
Singapore 424
Hefei 249
Ho Chi Minh City 223
Hanoi 162
Hong Kong 152
Ashburn 124
Santa Clara 110
Seoul 101
Amsterdam 93
Dallas 79
Bologna 46
Beijing 41
Boardman 37
Abidjan 28
Helsinki 27
Bengaluru 25
Ha Long 21
Tokyo 21
Chandler 20
Da Nang 19
Los Angeles 19
Quận Bình Thạnh 18
Dublin 17
Buffalo 16
Biên Hòa 15
Haiphong 15
Munich 15
Nuremberg 15
Jakarta 14
Can Tho 13
Milan 13
Thái Nguyên 13
Lappeenranta 12
New York 11
Chicago 10
Falkenstein 10
Phủ Lý 10
Princeton 10
Düsseldorf 9
Redondo Beach 9
San Jose 9
Vũng Tàu 9
Bắc Ninh 8
Frankfurt am Main 8
Mexico City 8
Vienna 8
Vinh 8
Hải Dương 7
Monzuno 7
Ninh Bình 7
Quận Một 7
Quận Phú Nhuận 7
Quận Sáu 7
Rome 7
Xi'an 7
Amman 6
Bắc Giang 6
Cesena 6
Quận Bảy 6
Sofia 6
Southend 6
Turku 6
Wilmington 6
Bern 5
Brooklyn 5
Changsha 5
Guangzhou 5
Lauterbourg 5
Nam Định 5
Quận Tân Phú 5
Rio de Janeiro 5
Shanghai 5
Turin 5
Brussels 4
Bạc Liêu 4
Can Giuoc 4
Fuzhou 4
Lấp Vò 4
Qingdao 4
Ravenna 4
San Francisco 4
São Paulo 4
Tam Bình 4
Thái Bình 4
Tongling 4
Warsaw 4
Yubileyny 4
Bagnacavallo 3
Berlin 3
Boydton 3
Brno 3
Bến Cầu 3
Chengdu 3
Dongguan 3
Fort Worth 3
Huế 3
Joinville 3
Long An 3
Salt Lake City 3
Springfield 3
Totale 2.573
Nome #
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 320
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 314
HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer 260
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 159
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy 136
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer 134
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis 129
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure 127
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 116
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment 115
Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient 111
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 104
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 104
Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity 101
Moving beyond parp inhibition: Current state and future perspectives in breast cancer 92
Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond 89
ANTIANGIOGENIC AGENTS ARE INEFFECTIVE TO INCREASE COMPLETE RESPONSE RATE IN MRCC. A META-ANALYSIS 88
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report 87
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 84
Case Report: Analysis of Plasma Extracellular Vesicles in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient 83
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 75
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 63
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial. 54
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 54
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer 51
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 50
Are we ready to use TMB in breast cancer clinical practice? 49
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 43
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? 42
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 41
Atezolizumab plus Nab-paclitaxel in PD-L1–Positive TNBC—Letter 40
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 37
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 34
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough? 32
Germline BRCA-mutated metastatic breast cancer with positive hormone receptor 31
Precision medicine: PI3K targeting in advanced breast cancer 17
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report 13
Ribociclib and endocrine therapy in breast cancer 12
The promise of liquid biopsy in cancer: A clinical perspective 12
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET 9
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study 6
Eribulin in brain metastases of breast cancer: Outcomes of the EBRAIM prospective observational trial 4
Totale 3.522
Categoria #
all - tutte 8.968
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.968


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202257 0 0 0 4 4 0 3 2 0 9 24 11
2022/2023128 5 11 5 16 7 13 2 8 33 4 9 15
2023/2024143 1 6 1 5 2 7 9 6 66 17 11 12
2024/2025976 35 119 77 68 156 58 40 31 7 89 73 223
2025/20262.218 712 453 424 281 253 69 26 0 0 0 0 0
Totale 3.522